Atherosclerosis
Volume 188, Issue 2 , Pages 274-280 , October 2006

Efficacy of peroxisome proliferative activated receptor (PPAR)-α ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models

Received 11 June 2005 ,Revised 31 October 2005 ,Accepted 31 October 2005.

References 

  1. Kakuta T, Currier JW, Haudenschild CC, et al. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis following angioplasty in the hypercholesterolemic rabbit model. Circulation. 1994;89:2809–2815
  2. Andersen HR, Maeng M, Thorwest M, et al. Remodeling rather than neointimal formation explains luminal narrowing after deep vessel wall injury. Insights from a porcine (re)stenosis model. Circulation. 1996;93:1716–1724
  3. Pels K, Labinaz M, O’Brien ER. Arterial wall neovascularization—potential role in atherosclerosis and restenosis. Jpn Circ J. 1997;61:893–904
  4. Pels K, Labinaz M, Hoffert C, et al. Adventitial angiogenesis early after coronary angioplasty correlation with arterial remodeling. Arterioscler Thromb Vasc Biol. 1999;19:229–238
  5. Chavakis T, Cines DB, Rhee JS, et al. Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. FASEB J. 2004;18:1306–1308
  6. Lai WK, Adams DH. Angiogenesis and chronic inflammation; the potential for novel therapeutic approaches in chronic liver disease. J Hepatol. 2005;42:7–11
  7. Devchand PR, Keller H, Peters JM, et al. The PPAR-α-leukotriene B4 pathway to inflammation control. Nature. 1996;384:39–43
  8. Hill MR, Clarke S, Rodgers K, et al. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia. Infect Immun. 1999;67:3488–3493
  9. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth muscle cells is inhibited by PPAR-α but not by PPAR-γ activators. Nature. 1998;393:790–793
  10. Delerive P, Gervois P, Fruchart JC, et al. Induction of IκBα expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferators-activated receptor-alpha activators. J Biol Chem. 2000;275:36703–36707
  11. Froman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferators-activated receptors alpha and delta. Proc Natl Acad Sci USA. 1997;94:4312–4317
  12. Kliewer SA, Sundseth SS, Jones SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with the peroxisome proliferators-activated receptor α and γ. Proc Natl Acad Sci USA. 1997;94:4318–4323
  13. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088–2093
  14. Schwartz RS, Murphy JG, Edwards WD, et al. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation. 1990;82:2190–2200
  15. Carter AJ, Laird JR, Farb A, et al. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol. 1994;24:1398–1405
  16. O’Brien ER, Garvin MR, Stewart DK, et al. Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb. 1994;14:883–894
  17. O’Brien ER, Garvin MR, Dev R, et al. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol. 1995;145:883–894
  18. Rogers C, Welt FG, Karnovsky MJ, et al. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol. 1996;16:1312–1318
  19. Okamoto E, Couse T, De Leon T, et al. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation. 2001;104:2228–2235
  20. Marx N, Sukhova GK, Collins T, et al. PPAR-α activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999;99:3125–3131
  21. Varet J, Vincent L, Mirshahi P, et al. Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci. 2003;60:810–819
  22. Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation. 1996;94:35–43
  23. Ignatescu MC, Gharehbaghi-Schnell E, Hassan A, et al. Expression of the angiogenic protein, platelet-derived endothelial cell growth factor, in coronary atherosclerotic plaques: in vivo correlation of lesional microvessel density and constrictive vascular remodeling. Arterioscler Thromb Vasc Biol. 1999;19:2340–2347
  24. Smith JD, Bryant SR, Couper LL, et al. Soluble transforming growth factor-β type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Circ Res. 1999;84:1212–1222
  25. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905–910
  26. Ericsson CG, Nilsson J, Grip L, et al. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). Am J Cardiol. 1997;80:1125–1129

PII: S0021-9150(05)00722-7

doi: 10.1016/j.atherosclerosis.2005.10.047

Atherosclerosis
Volume 188, Issue 2 , Pages 274-280 , October 2006

Article Tools

* Image Usage & Resolution